[

gilead

]

Latest from gilead

WHO advises against Gilead’s Remdesivir for all hospitalised Covid-19 patients

The advice is another setback for the drug, which grabbed worldwide attention as a potentially effective treatment for Covid-19 in the summer after early trials showed some promise.
Two ampules of Ebola drug Remdesivir are pictured during a news conference at the University Hospital Eppendorf (UKE) in Hamburg, Germany.(Reuters File Photo)
Two ampules of Ebola drug Remdesivir are pictured during a news conference at the University Hospital Eppendorf (UKE) in Hamburg, Germany.(Reuters File Photo)
Updated on Nov 20, 2020 05:48 AM IST
Copy Link
London | ByReuters | Posted by Kanishka Sarkar

Nations mulling Gilead’s Covid-19 drug should consider trial flop, too: WHO

Health officials reviewing Gilead Science Inc’s remdesivir against Covid-19 should consider all evidence, including a trial in which the medicine failed, before giving it the green light, the top WHO scientist said on Friday.
The U.S. Food and Drug Administration on Thursday approved Gilead’s antiviral drug for treating patients hospitalized with Covid-19, making it the first and only drug approved for the disease in the United States.(File photo for representation)
The U.S. Food and Drug Administration on Thursday approved Gilead’s antiviral drug for treating patients hospitalized with Covid-19, making it the first and only drug approved for the disease in the United States.(File photo for representation)
Updated on Oct 24, 2020 05:40 PM IST
Copy Link
Geneva/Zurich | ByReuters | Posted by Niyati Singh

Covid-19: Gilead’s Remdesivir is first virus drug to get FDA approval

Regulators had granted an emergency-use authorization for remdesivir earlier this year, and since then the drug has become a widely used therapy in hospitalized Covid-19 patients. It was given to President Donald Trump this month when he was diagnosed with the virus.
A bottle containing the drug Remdesivir is shown by a health worker at the Institute of Infectology of Kenezy Gyula Teaching Hospital of the University of Debrecen in Debrecen, Hungary.(AP)
A bottle containing the drug Remdesivir is shown by a health worker at the Institute of Infectology of Kenezy Gyula Teaching Hospital of the University of Debrecen in Debrecen, Hungary.(AP)
Updated on Oct 23, 2020 04:22 AM IST
Copy Link
ByBloomberg | Posted by Shivani Kumar

Gilead questions WHO study that cast doubts on drug’s Covid-19 benefits

The American company told Reuters the data appeared inconsistent, the findings were premature and that other studies had validated the drug’s benefits.
The WHO trial was conducted in 11,266 adult patients in more than 30 countries. The evidence was conclusive, the WHO said.(Reuters)
The WHO trial was conducted in 11,266 adult patients in more than 30 countries. The evidence was conclusive, the WHO said.(Reuters)
Published on Oct 16, 2020 02:35 PM IST
Copy Link
Reuters | ByReuters| Posted by Susmita Pakrasi

Remdesivir, hydroxychloroquine did not cut hospital stay or mortality in Covid-19 patients: WHO

The study found the regimens appeared to have little or no effect on 28-day mortality or the length of the in-hospital course among patients hospitalized with Covid-19, the WHO said on Thursday.
A bottle containing the drug Remdesivir is shown by a health worker at the Institute of Infectology of Kenezy Gyula Teaching Hospital of the University of Debrecen in Debrecen, Hungary on Thursday.(AP Photo)
A bottle containing the drug Remdesivir is shown by a health worker at the Institute of Infectology of Kenezy Gyula Teaching Hospital of the University of Debrecen in Debrecen, Hungary on Thursday.(AP Photo)
Updated on Oct 16, 2020 08:47 AM IST
Copy Link
Reuters | ByReuters | Posted by Kanishka Sarkar

Gilead to buy cancer drugmaker Immunomedics for $21 billion

Gilead Sciences Inc will acquire biotech company Immunomedics Inc for $21 billion, a move that will strengthen its cancer portfolio by gaining access to a promising drug, the two companies said in a joint statement on Sunday.
Gilead said it would issue a tender offer to buy all the outstanding shares of Immunomedics for $88 per share, representing a premium of about 108% over their last closing price of $42.25 on Sept. 11.(File photo for representation)
Gilead said it would issue a tender offer to buy all the outstanding shares of Immunomedics for $88 per share, representing a premium of about 108% over their last closing price of $42.25 on Sept. 11.(File photo for representation)
Updated on Sep 14, 2020 03:30 PM IST
Copy Link
ByReuters | Posted by Niyati Singh

US hospitals turn down remdesivir, limit use to sickest Covid-19 patients

The Food and Drug Administration has allowed more liberal remdesivir use, but 6 out of 8 major hospital systems contacted by Reuters said they were not using it for moderate cases.
A lab technicians holds the coronavirus disease (Covid-19) treatment drug
A lab technicians holds the coronavirus disease (Covid-19) treatment drug "Remdesivir" at Eva Pharma Facility in Cairo, Egypt.(REUTERS)
Updated on Sep 12, 2020 06:44 PM IST
Copy Link
ByReuters | Posted by Arpan Rai

UK’s Hikma starts manufacturing Covid-19 treatment remdesivir for Gilead

The company will supply the first batches of the antiviral drug “soon,” and Gilead is expected to distribute the treatment, which was the first to be greenlit for the illness caused by the new coronavirus.
“The terms of the deal are confidential, we are simply a contract manufacturer for Gilead - they order products from us as they expect the sales to be,” CEO Siggi Olafsson told Reuters on Friday.(REUTERS)
“The terms of the deal are confidential, we are simply a contract manufacturer for Gilead - they order products from us as they expect the sales to be,” CEO Siggi Olafsson told Reuters on Friday.(REUTERS)
Published on Aug 07, 2020 02:00 PM IST
Copy Link
Reuters | ByReuters| Posted by Susmita Pakrasi

Gilead analysis shows remdesivir reduced Covid death risk, but more trials needed

Remdesivir has been at the forefront of the global battle against Covid-19 after the intravenously administered medicine helped shorten hospital recovery times, according to data in April from a separate US government trial.
The US government trial in April showed that patients given remdesivir recovered 31% faster than those given a placebo.(Reuters file photo)
The US government trial in April showed that patients given remdesivir recovered 31% faster than those given a placebo.(Reuters file photo)
Published on Jul 11, 2020 08:53 AM IST
Copy Link
Reuters | ByReuters| Posted by: Harshit Sabarwal

Gilead says additional data on remdesivir shows improved clinical recovery

Gilead said it analyzed data from 312 patients treated in a late-stage study and a separate real-world retrospective cohort of 818 patients with similar characteristics and disease severity as in the study.
An ampule of Ebola drug Remdesivir is pictured during a news conference at the University Hospital Eppendorf (UKE) in Hamburg, Germany.(Reuters file photo)
An ampule of Ebola drug Remdesivir is pictured during a news conference at the University Hospital Eppendorf (UKE) in Hamburg, Germany.(Reuters file photo)
Updated on Jul 10, 2020 07:16 PM IST
Copy Link
ByReuters | Posted by Shivani Kumar

Remdesivir shortage hits Delhi as requirement soars

Doctors blame increased demand and limited supply of the medicine for its shortage since the Union health ministry on June 13 allowed its emergency use for treating Covid-19 patients with moderate symptoms.
An increase in cases around the country has seen more doctors prescribing the drug , but supply hasn’t increased proportionately. Patients prescribed the drug are typically given six doses (each is an injection).(REUTERS)
An increase in cases around the country has seen more doctors prescribing the drug , but supply hasn’t increased proportionately. Patients prescribed the drug are typically given six doses (each is an injection).(REUTERS)
Updated on Jul 09, 2020 01:17 AM IST
Copy Link
Hindustan Times, New Delhi | By

Gilead prices Covid-19 drug candidate remdesivir at $2,340 per patient

The price tag is below the $5,080 per course recommendation by U.S. drug pricing research group, the Institute for Clinical and Economic Review (ICER), last week.
Gilead Sciences Inc has priced its Covid-19 drug candidate remdesivir at $2,340 for a five-day treatment in the United States and some other developed countries, potentially reflecting looming competition from a cheap steroid.(File photo for representation)
Gilead Sciences Inc has priced its Covid-19 drug candidate remdesivir at $2,340 for a five-day treatment in the United States and some other developed countries, potentially reflecting looming competition from a cheap steroid.(File photo for representation)
Updated on Jun 29, 2020 07:53 PM IST
Copy Link
ByReuters | Posted by Niyati Singh

European regulator recommends remdesivir for Covid-19 treatment

The European healthcare regulator has recommended the conditional approval of Gilead Sciences Inc’s antiviral treatment, remdesivir, for use in Covid-19 patients, making it the first treatment to be on track to be green-lit in the continent.
The price of the drug in the region is not yet known. In the United States, it could be priced up to $5,080 per course, while Indian generic drugmakers will sell the treatment between 5,000 rupees to 6,000 rupees ($66.13-$79.35).(File photo for representation)
The price of the drug in the region is not yet known. In the United States, it could be priced up to $5,080 per course, while Indian generic drugmakers will sell the treatment between 5,000 rupees to 6,000 rupees ($66.13-$79.35).(File photo for representation)
Updated on Jun 26, 2020 04:24 AM IST
Copy Link
ByReuters | Posted by Niyati Singh

Domestic pharma giants-- Cipla, Hetero got DCGI’s nod to manufacture, sell anti-viral Remdesivir drug to fight Covid-19

With this development, India is soon to begin the domestic production of anti-viral drug remdesivir which would have efficacy, stability, safety for “restricted emergency use” on Covid-19 patients, official added.
Gilead had signed non-exclusive voluntary licensing agreements with five generic pharma firms -- Cipla, Jubilant Life Sciences, Hetero, BRD and Mylan to manufacture and distribute remdesivir, a potential antiviral therapy for Covid-19.(Reuters)
Gilead had signed non-exclusive voluntary licensing agreements with five generic pharma firms -- Cipla, Jubilant Life Sciences, Hetero, BRD and Mylan to manufacture and distribute remdesivir, a potential antiviral therapy for Covid-19.(Reuters)
Published on Jun 21, 2020 09:11 AM IST
Copy Link
New Delhi, India | ByAsian News International | Posted by: Shivani Kumar

Covid-19 vaccine update: Russia begins clinical trials, Gilead to enrol pediatric patients in remdesivir testing

From experimental drug remdesivir making strides to generic steroid drug dexamethasone emerging as the first Covid-19 drug, the race to developing the antidote to Covid-19 is getting more interesting by the day.
File photo: A researcher at Protein Sciences reaches for a vial in a lab in Meriden, Conn. The biotech company is currently researching a vaccine for Covid-19.(AP)
File photo: A researcher at Protein Sciences reaches for a vial in a lab in Meriden, Conn. The biotech company is currently researching a vaccine for Covid-19.(AP)
Updated on Jun 18, 2020 12:49 PM IST
Copy Link
Hindustan Times, New Delhio | Byhindustantimes.com | Edited by Sparshita Saxena

Dr Reddy’s, Biocon’s Syngene among 4 more firms in pact with Gilead for Covid-19 drug remdesivir

Dr Reddy’s Laboratories Ltd, Biocon arm Syngene International Ltd, Zydus Cadila Ltd, and Egypt-based Eva Pharma Pvt Ltd are the companies Gilead has entered into non-exclusive voluntary licensing agreements with.
An ampule of remdesivir is pictured during a news conference as the spread of coronavirus disease (Covid-19) continues.(REUTERS)
An ampule of remdesivir is pictured during a news conference as the spread of coronavirus disease (Covid-19) continues.(REUTERS)
Published on Jun 13, 2020 03:39 PM IST
Copy Link
Hindustan Times, New Delhi | Byhindustantimes.com | Edited by Meenakshi Ray

Zydus Cadila inks licensing pact with Gilead for remdesivir

Remdesivir, the investigational drug from Gilead Sciences Inc, has been issued an ‘emergency use authorisation’ (EUA) by the United States Food and Drug Administration (USFDA) to treat patients suffering from severe symptoms of coronavirus, Zydus Cadila said in a statement.
Two ampules of Remdesivir are pictured during a news conference at the University Hospital Eppendorf (UKE) in Hamburg, Germany(REUTERS)
Two ampules of Remdesivir are pictured during a news conference at the University Hospital Eppendorf (UKE) in Hamburg, Germany(REUTERS)
Updated on Jun 12, 2020 09:28 PM IST
Copy Link
New Delhi | ByPress Trust of India

Gilead’s remdesivir slows progression of Covid-19 in monkeys: Study

In the study, macaques that received remdesivir did not show signs of respiratory disease and had reduced damage to the lungs, according to the study authors.
Vials of investigational coronavirus disease (COVID-19) treatment drug remdesivir are capped at a Gilead Sciences facility in La Verne, California, U.S.(Reuters)
Vials of investigational coronavirus disease (COVID-19) treatment drug remdesivir are capped at a Gilead Sciences facility in La Verne, California, U.S.(Reuters)
Updated on Jun 09, 2020 03:43 PM IST
Copy Link
Reuters | ByReuters| Posted by Susmita Pakrasi

AstraZeneca eyes potential merger with Gilead Sciences

AstraZeneca, valued at $140 billion, is the U.K.’s biggest drugmaker by market capitalization and has developed treatments for conditions from cancer to cardiovascular disease.
Shares of AstraZeneca have risen about 41% over the past 12 months, making it the best performer on a Bloomberg Intelligence index of major Western pharmaceutical companies.(REUTERS)
Shares of AstraZeneca have risen about 41% over the past 12 months, making it the best performer on a Bloomberg Intelligence index of major Western pharmaceutical companies.(REUTERS)
Published on Jun 08, 2020 04:43 AM IST
Copy Link
Bloomberg | ByBloomberg

Taiwan approves Gilead’s remdesivir to treat Covid-19

California-based Gilead has said it will donate 1.5 million doses of remdesivir, enough to treat at least 140,000 patients, to combat the global pandemic.
Governments are racing to bolster supplies of remdesivir, which US regulators this month approved for emergency use.(via REUTERS)
Governments are racing to bolster supplies of remdesivir, which US regulators this month approved for emergency use.(via REUTERS)
Published on May 30, 2020 12:13 PM IST
Copy Link
Taipei | ByReuters | Posted by: Prashasti Singh

Roche, Gilead to test drug cocktail against severe Covid-19

Roche said in a statement that it had joined forces with Gilead for a global phase III clinical trial evaluating the safety and efficacy of using tocilizumab combined with remdesivir in hospitalised patients with severe Covid-19 pneumonia.
The clinical trial is due to begin in early June with approximately 450 patients participating in the United States, Canada and Europe.(Reuters)
The clinical trial is due to begin in early June with approximately 450 patients participating in the United States, Canada and Europe.(Reuters)
Updated on May 29, 2020 08:33 AM IST
Copy Link
Agence France-Presse | ByAgence France-Presse, Zurich

Jubilant Life Sciences Limited ties up with Gilead for remdesivir

Remdesivir, an investigational anti-viral therapy developed by Gilead, received Emergency Use Authorisation (EUA) by USFDA to treat Covid-19.
An ampule of remdesivir is pictured at the University Hospital Eppendorf (UKE) in Hamburg, Germany, on April 8.(Reuters Photo)
An ampule of remdesivir is pictured at the University Hospital Eppendorf (UKE) in Hamburg, Germany, on April 8.(Reuters Photo)
Updated on May 12, 2020 09:31 PM IST
Copy Link
Hindustan Times, New Delhi | ByHT Correspondent

Covid-19 update: US firm Gilead in talks with Indian drug companies to produce remdesivir

Coronavirus update: The discussion is taking place about their ability, under voluntary licenses, to produce remdesivir for Europe, Asia and the developing world through at least 2022.
India is part of the World Health Organisation’s Solidarity Trials for the cure of Covid-19 and has received 1000 doses of the drug for testing.(Reuters File Photo)
India is part of the World Health Organisation’s Solidarity Trials for the cure of Covid-19 and has received 1000 doses of the drug for testing.(Reuters File Photo)
Updated on May 07, 2020 07:10 AM IST
Copy Link
Hindustan Times, New Delhi | By

US okays remdesivir for emergency Covid-19 use

The emergency authorisation allows products to be used for treatment without full data on their safety and efficacy, which has to be still submitted as trials continue.
Angry protesters hold banners during a demonstration demanding the reopening of the US economy, in Chicago, Illinois.
Angry protesters hold banners during a demonstration demanding the reopening of the US economy, in Chicago, Illinois.
Published on May 03, 2020 03:27 AM IST
Copy Link
Hindustan Times, New Delhi/Washington | BySanchita Sharma and Yashwant Raj, New Delhi/ Washington

US issues emergency approval for remdesivir for Covid-19 patients

President Donald Trump announced the news at the White House alongside Gilead CEO Daniel O’Day and Food and Drug Administration Commissioner Stephen Hahn.
The FDA acted after preliminary results from a government-sponsored study showed that the drug, remdesivir, shortened the time to recovery by 31%, or about four days on average, for hospitalized COVID-19 patients.(REUTERS)
The FDA acted after preliminary results from a government-sponsored study showed that the drug, remdesivir, shortened the time to recovery by 31%, or about four days on average, for hospitalized COVID-19 patients.(REUTERS)
Updated on May 02, 2020 04:49 AM IST
Copy Link
Washington | ByAssociated Press

Gilead stuck amid profit and virus drug

Details from a US government study and a separate trial conducted by the company itself suggest remdesivir may become the first medication approved to treat the novel coronavirus, which has sickened 3.2 million people worldwide and killed 233,000.
A lab technician visually inspects a filled vial of investigational coronavirus disease (COVID-19) treatment drug remdesivir at a Gilead Sciences facility in La Verne, California(via REUTERS)
A lab technician visually inspects a filled vial of investigational coronavirus disease (COVID-19) treatment drug remdesivir at a Gilead Sciences facility in La Verne, California(via REUTERS)
Published on May 02, 2020 03:24 AM IST
Copy Link
Minneapolis | ByBloomberg

Antiviral drug shows some hope in US govt-run study

Gilead shares jumped as much as 7.1% Wednesday after the company’s statement. The news appeared to boost the entire U.S. stock market as well, with the S&P 500 gaining 2.4% despite data showing a deep contraction in the U.S. economy in the first quarter of the year.
The company issued a news release early Wednesday commenting on the study from the U.S. National Institute of Allergy and Infectious Diseases without providing details of the results.(REUTERS)
The company issued a news release early Wednesday commenting on the study from the U.S. National Institute of Allergy and Infectious Diseases without providing details of the results.(REUTERS)
Updated on Apr 30, 2020 04:56 AM IST
Copy Link
New York | ByBloomberg

Antiviral remdesivir showed ‘no significant benefit’ in virus patients

In a study among more than 200 Covid-19 patients in Wuhan, China, published in The Lancet, doctors found no positive effects of administering the drug compared with a control group of adults.
In this file photo one vial of the drug Remdesivir is viewed during a press conference about the start of a study.(AFP file photo)
In this file photo one vial of the drug Remdesivir is viewed during a press conference about the start of a study.(AFP file photo)
Updated on Apr 29, 2020 10:48 PM IST
Copy Link
Hindustan Times, Paris | ByAgence France-Presse

Top Chinese lab files patent for US drug to fight Coronavirus cases

The research led by the Wuhan Institute of Virology (WIV) found that two drugs - remdesivir and the generic chloroquine - could inhibit or check the Coronavirus.
A local resident returning from travel registers with an official at the entry gate of a residential neighborhood in Shanghai, China, on Wednesday, Feb. 5, 2020.(Bloomberg)
A local resident returning from travel registers with an official at the entry gate of a residential neighborhood in Shanghai, China, on Wednesday, Feb. 5, 2020.(Bloomberg)
Updated on Feb 05, 2020 10:38 PM IST
Copy Link
Hindustan Times, Beijing | BySutirtho Patranobis

Margaret Atwood is one of this year’s Booker Prize winner. Here are her top 5 books you must read

Canadian author Margaret Atwood and British author Bernardine Evaristo were awarded the Booker Prize for Fiction 2019 last night in London. Read on for Atwood’s five most-loved novels you must read.
Author Margaret Atwood reads an extract during the launch of her new novel The Testaments at a book store in London, Britain late September 9, 2019. REUTERS/Dylan Martinez(REUTERS)
Author Margaret Atwood reads an extract during the launch of her new novel The Testaments at a book store in London, Britain late September 9, 2019. REUTERS/Dylan Martinez(REUTERS)
Updated on Oct 15, 2019 02:19 PM IST
Copy Link
Hindustan Times, Delhi | By
SHARE
  • 1
  • 2
  • ...
Story Saved
×
Saved Articles
Following
My Reads
Sign out
New Delhi 0C
Monday, January 24, 2022